Deutsche Märkte öffnen in 7 Stunden 41 Minuten

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
59,94+0,46 (+0,77%)
Börsenschluss: 04:00PM EDT
60,62 +0,68 (+1,13%)
Nachbörse: 06:22PM EDT

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700
https://www.incyte.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter2.524

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Herve HoppenotCEO & Chairman2,9MN/A1960
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development2,03MN/A1963
Ms. Christiana Stamoulis MBAExecutive VP & CFO1,18MN/A1971
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive VP & GM of North America1,01MN/A1958
Dr. Steven H. Stein M.D.Executive VP & Chief Medical Officer1,32MN/A1967
Mr. Thomas TrayVP of Finance, Chief Accounting Officer & ControllerN/AN/A1978
Mr. Michael James MorrisseyExecutive VP & Head of Global Technical OperationsN/AN/A1964
Mr. Ben StrainHead of Investor RelationsN/AN/AN/A
Sheila A. DentonExecutive VP, General Counsel & Corporate SecretaryN/AN/A1966
Ms. Pamela M. MurphyVice President of Investor Relations & Corporate CommunicationsN/AN/A1951
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Corporate Governance

Incyte Corporations ISS Governance QualityScore, Stand 1. Juni 2024, lautet 7. Die grundlegenden Scores sind Audit: 5, Vorstand: 7, Shareholderrechte: 6, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.